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A B S T R A C TThe quantitative assessment of the potential influence of unmeasured
confounders in the analysis of observational data is rare, despite reliance
on the ‘‘no unmeasured confounders’’ assumption. In a recent compar-
ison of costs of care between two treatments for type 2 diabetes using
a health care claims database, propensity score matching was imple-
mented to adjust for selection bias though it was noted that information
on baseline glycemic control was not available for the propensity model.
Using data from a linked laboratory file, data on this potential ‘‘unmea-
sured confounder’’ were obtained for a small subset of the original
sample. By using this information, we demonstrate how Bayesian
modeling, propensity score calibration, and multiple imputation can
utilize this additional information to perform sensitivity analyses to
quantitatively assess the potential impact of unmeasured confounding.
Bayesian regression models were developed to utilize the internal
validation data as informative prior distributions for all parameters,see front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.10.012
lilly.com.
ndence to: Douglas Faries, Eli Lilly & Company, Lillretaining information on the correlation between the confounder and
other covariates. While assumptions supporting the use of propensity
score calibration were not met in this sample, the use of Bayesian
modeling and multiple imputation provided consistent results, suggest-
ing that the lack of data on the unmeasured confounder did not have a
strong impact on the original analysis, due to the lack of strong
correlation between the confounder and the cost outcome variable.
Bayesian modeling with informative priors and multiple imputation
may be useful tools for unmeasured confounding sensitivity analysis in
these situations. Further research to understand the operating character-
istics of these methods in a variety of situations, however, remains.
Keywords: Bayesian methods, confounding, robustness, sensitivity
analyses.
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The use of retrospective observational research as a tool for
medical decision making, particularly with data from health care
claims databases and electronic medical records, has been grow-
ing in recent years. With large and heterogeneous populations of
patients, such observational databases are a rich source of usual
care data, which can potentially address a variety of medical
questions [1,2]. The use of such data for comparative effectiveness,
however, is challenged by selection bias and potential for unmea-
sured confounding [3–5]. Patients are not randomized to treat-
ments and thus comparisons between treatment groups are
subject to bias due to the many factors that influence treatment
choices in usual care practice. Statistical adjustment for measured
confounders is possible, such as through propensity score adjust-
ment. The validity of such methods, however, relies on the
assumption that there are no unmeasured confounders. That is,
there are no factors related to both treatment and outcome that
are not collected and appropriately utilized in the analysis. As this
assumption cannot be verified, observational data have lower
internal validity and are lower on the hierarchy of evidence
relative to randomized clinical trials [6–9].In prospective observational studies, a researcher can specify the
collection of data on known confounders; however, this opportunity
does not exist in retrospective database research. While researchers
look for proxies for such known confounders within the existing
database, the degree to which this addresses the confounding is
unknown. In addition, unknown confounders may exist and without
randomization such variables will cause the standard analyses to be
biased. To ensure the robustness of the observational research
findings, it is important to conduct sensitivity analyses to assess
the potential impact of unmeasured confounding [4,9–10].
While many researchers mention the limitations on infer-
ences from their work due to unmeasured confounding, few
directly assess the potential impact in a quantitative fashion
[10,11]. Even when no or limited additional data on the unmea-
sured confounders are available, there are several methods that
can be utilized to assess sensitivity for unmeasured confounding,
including the Rule Out [10] and Bayesian modeling with non-
informative priors [12]. The Rule Out approach uses a simple
model to quantify the level of unmeasured confounding neces-
sary to eliminate the observed treatment difference (e.g., moves
the risk ratio to 1). Researchers can then assess whether such
a level of confounding is plausible for their scenario.Society for Pharmacoeconomics and Outcomes Research (ISPOR).
y Corporate Center, Indianapolis, IN 46285, USA
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 2 5 9 – 2 6 6260Data on a known unmeasured confounder may be available
external to the study (‘‘external information’’), such as in a
related study or survey data [13–15]. Bayesian approaches
[11,12,16] are a natural fit as the uncertainty in the ‘‘external
information’’ can be modeled as part of an informative prior
distribution. The use of external data, however, requires trans-
portability between populations and typically faces difficulty
accounting for the correlation between unmeasured confounders
and measured covariates already in the original analysis. The
impact of an unmeasured confounder can clearly depend on the
extent to which a missing variable is related to other variables
in the analysis. This problem can be addressed directly when
‘‘internal information’’ is available. For example, chart review
data could be obtained on a subsample of the patients in
administrative claims database analysis and could be used as
‘‘internal information.’’
Methods utilizing internal data include Bayesian modeling,
propensity score calibration (PSC) [17], and multiple imputation
[18,19]. Bayesian approaches can utilize the internal data in their
prior structures. PSC is based on measurement error methodol-
ogy and accounts for the correlation between the confounder and
other variables already in the full model. The method, however,
depends on the assumption that the association between the
unmeasured confounder and outcome is in the same direction as
the association between the measured confounders and the
outcome. This clearly will not be valid in all scenarios, and the
method performs poorly when this assumption is violated [20].
When some internal data on the ‘‘unmeasured’’ confounder
exist, the issue can be viewed as a missing data problem, and
methods such as multiple imputation can be utilized. Incorporating
the outcome variable in the imputer’s model allows for full flexibility
in regard to the relationship of the unmeasured confounder with the
outcome variable—a relationship that is restricted in the PSC
approach. The properties of such multiple imputation approaches
when the majority of the data is missing, as in ‘‘unmeasured’’
confounding scenarios, however, are not well known. This multiple
imputation approach also falls within the general probabilistic
resampling framework discussed by Gustafson and McCandless [11].
A recent study [21] compared health care costs for patients
initiating exenatide (referred to as Treatment 1 throughout the
remainder of this article) versus insulin glargine (Treatment 2).
This was a retrospective claims database study, and information
on some potential confounders, such as the level of glycemic
control (measured by glycoslylated hemoglobin [Hb], or Hb A1c)
was minimal. Indeed, Hb A1c values were recorded only for 25% of
the patients during the preinitiation period, and so there was no
adjustment for glycemic control in the primary analysis. In this
study, we performed a post-hoc analysis to demonstrate methods
for assessing the impact of the unmeasured confounding in the
case in which there is internal data—such as glycemic control in
this example. Specifically, three different methods incorporating
the internal data were assessed: 1) Bayesian modeling, 2) multiple
imputation, and 3) PSC. A Rule Out approach was also used as an
initial assessment of the robustness of the results to potential
unmeasured confounding.Methods
Database
The objective of the original analysis was to compare the total
health care costs for type 2 diabetes patients initiating one of two
treatments with a 12-month follow-up period. The analysis was
performed by using an administrative claims database from i3
InVision. This database includes medical and prescription claims
from more than 30 million patients throughout the United Statesduring the study time period. See Pawaskar et al. [21] for further
details concerning the database and population for this analysis.
In brief, patients were included in this study if they received
at least one new prescription for either of the diabetic medica-
tions between April 1, 2005 (the earliest month both medications
were on the market in the United States), and June 30, 2007 (the
latest available data at the time of the original analysis), and
must have had at least one diagnosis for type 2 diabetes
identified by using International Classification of Disease, Ninth
Revision, Clinical Modification during the preindex period. The first
prescription date for study medication was identified as the
index date. The preindex period was defined as a 6-month period
prior to the index date (i.e., 6 months before the first prescription
of index medication) and the postindex period was defined as a
12-month follow-up period after the index date. The database
contained 93,345 patients initiating either treatment during the
time period, with 10,074 meeting all inclusion/exclusion criteria
(the largest exclusion of more than 41,000 patients due to a
diagnosis of type I or gestational diabetes). Of the 10,074 patients
in the analysis data set, 7,255 patients were in the Treatment 1
cohort, 2,819 in the Treatment 2 cohort, and baseline Hb A1c data
were available for only approximately 25% of these patients.
Adjustment and Outcomes Variables
Total health care cost over the 12-month follow-up period was
the primary outcome variable for the previous study and thus
is the outcome of interest for this analysis. The assessment of
cost data adds additional analytic challenges in part due to the
skewness of the data [22,23] but is an important outcome for the
health care payer. Patients were not randomly assigned to
treatment groups. Consequently, many differences between the
populations of patients prescribed each treatment in usual care
were expected and adjustment for baseline differences was
necessary. The health care claims database allowed for the
assessment of patient demographics, comorbidities, complica-
tions, resource use, and costs of care in the 6-month preinitation
period. No data on the other potential confounders such as
weight, body mass index (BMI), and duration of diabetes, how-
ever, were available. Only limited data on glycemic control,
measured by Hb A1c, were available in the subset of patients.
Statistical Methods
In the original analysis, the two treatment cohorts were matched
by using a propensity score greedy 1:1 algorithm. The differences in
total costs in the 12-month follow-up period between treatments
cohorts were estimated by using a nonparametric bootstrapping
test. The propensity model included patient demographics, general
health status (measured by Charlson comorbidity index), medical
comorbidities, diabetes-related complications, medication use
(including prior antidiabetic medications), health care resource
utilization (hospitalizations, emergency room visits, endocrinolo-
gist visits), and medical costs during the 6-month preindex period,
but not Hb A1c. Sensitivity analysis including propensity score
stratified bootstrapping [24] and generalized linear regression
models [25] was used to ensure the generalizability of results from
matched cohorts to the entire study population. This study also
performed a separate generalized linear model in the subgroup of
patients for whom a preindex Hb A1c value was available, to
estimate the mean total costs when controlling for patients’
glycemic control at the baseline.
The current analysis considered several other techniques to
assess the potential impact of the exclusion of glycemic control
information from the original analysis: 1) Bayesian modeling
with internal validation, 2) multiple imputation, and 3) PSC.
As the first step of the analysis, a Rule Out approach was included.
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assumed a single unmeasured confounder (Hb A1c ) dichotomized
as ‘‘elevated’’ (47%) or not. First, we considered all possible values
of the association between treatment cohort and Hb A1c, as
expressed by the difference in Pc0 and Pc1 (ranging from 1 to 1),
the proportions of patients in each cohort who meet the Hb A1c
condition. Second, we considered plausible values of the associa-
tion between Hb A1c and cost, defined as the confounding effect
(with values ranging from $50,000 to $50,000 in this example),
the difference in outcome (cost) for patients who do and do not
meet the Hb A1c criteria. Computations for the Rule Out approach
were based on the model below, which considers the observed
treatment difference (apparent mean difference) in total costs as a
function of the true treatment difference (fully adjusted mean
difference) multiplied by a bias factor that depends on the above
two associations:
AMD¼TMDþ PC0PC1ð Þ  CE:
In the Bayesian approach, we assumed a linear model for the
costs, and a logistic model for the unmeasured binary confoun-
der. That is we take
Y¼b0þb1 Xþl UþZ Zþe ð1Þ
log it P U¼1ð Þ ¼g0 þ g1 Xþg2 Z ð2Þ
where Y is a continuous random variable representing the total
health care costs, X and U denote dichotomous random variables
taking values 1 or 0 to indicate the treatment group and the
presence or absence of the unmeasured confounder, and
Z denotes a vector of measured covariates. For this analysis,
Z represented a single propensity score variable, which incorpo-
rated information from demographic, health status, comorbid-
ities, prior medication use, and prior health care resource
utilization and cost variables. The error terms were assumed to
be normal with SD s, though sensitivity analyses were performed
by using a gamma distribution due to the skewness of the cost
outcome data (see Appendix in Supplement Materials found at
doi: 10.1016/j.jval.2012.10.012 for details). Parameters l,g0,g1,g2
reflect the assumptions about the confounding effect and the
exposure of U, whose prior distribution can be obtained from
internal or external validation data. In our example, we treat the
data from the subset of patients with Hb A1c values as internal
validation data. Responses from patients without Hb A1c values
constitute the main study data. We use the model in Eq. 1 and
Eq. 2 for the main study data. The internal validation data was
modeled by using
Y¼b0þb1 Xþl U0 þZ Zþe ð3Þ
where
log it Pr U0 ¼1ð Þ ¼g0 þ g1 Xþg2 Z ð4Þ
and U0 denotes the covariate (i.e., Hb A1c in our example) that is
unmeasured in the main study but measured in the validation
study. For this analysis, Z represents the propensity score, using
the same propensity model described above. The posterior dis-
tribution (and therefore point and interval estimates) of the
model parameters is then obtained by using Markov chain Monte
Carlo sampling. By combining the internal validation and main
study data, the Bayesian estimators are adjusted for the unmea-
sured confounding. Details regarding the implementation and
WinBUGS code for the Bayesian modeling are provided in the
Appendix in Supplemental Materials found at doi: 10.1016/
j.jval.2012.10.012. Analyses were conducted by using the propen-
sity matched sample (n ¼ 5012) as this allowed for direct
comparison with the original analysis.
To perform the PSC analysis, we defined the error-prone
propensity score (PSEP) based on the propensity score model forthe original analysis that did not include Hb A1c (see Equation 5).
The gold standard propensity score (PSGS) model included all the
factors in the error-prone propensity model plus Hb A1c and was
computed in the subset of patients with Hb A1c data (see
Equation 6). While referred to as a ‘‘gold standard’’ by the PSC
literature, this is perhaps better noted as a ‘‘complete case’’
propensity score here, borrowing terminology from the missing
data literature. This is because the subsample was not chosen
randomly and the missing data mechanism for the Hb A1c is
unknown. Using the notation of Sturmer et al. [17],
PSEP¼Pr X¼19z1,z2,. . .,zn
  ð5Þ
PSGS¼Pr X¼19z1,z2,. . .,zn,u
  ð6Þ
where zi represents the measured confounders in the original
analysis and u represents Hb A1c. The measurement error model
is then
E½PSGS¼d0þd1Xþd2PSEP ð7Þ
To mimic the original analysis that used propensity score
matching, we implemented the calibration analysis by imputing
the estimated gold standard propensity scores and performing
both a matched (1:1 greedy algorithm) and stratified analysis
based on the estimated gold standard propensity scores. Direct
adjusted estimates could also be obtained per Sturmer et al. [17].
For the validity of PSC, one must assume that PSEP is independent
of outcome given PSGS and treatment. Practically, this means that
the direction of the confounding due to the unmeasured con-
founder is in the same direction as the confounding due to the
existing covariates (z1,y,zn). In addition to computing the corre-
lations among the variables one can assess surrogacy through
a likelihood ratio test comparing a model with the addition of
PSEP to a base model with only PSGS and treatment [20].
Based on related missing data work [18,19], multiple imputa-
tion of continuous Hb A1c values was performed by using the
Markov Chain Monte Carlo approach [26] with the original
propensity score, treatment, and outcome variable in the imputa-
tion model. Outcome was included in the imputation model to
allow for the association between the unmeasured confounding
and outcome to be driven by the data (as opposed to propensity
calibration where certain associations can invalidate the
approach). Five replications of the data set were created and for
each we performed a propensity score matched analysis, and then
pooled results across the replications. Because of the assumption
of multivariate normality in the Markov chain Monte Carlo
approach and the uncertainty with the number of replications
necessary given the high proportion of missing data, sensitivity
analyses were performed by using a nonparametric imputation
approach (propensity based) and up to 20 replications.Results
A total of 10,074 patients were included in the analysis popula-
tion (Treatment 1: n ¼ 7255, Treatment 2: n ¼ 2819), with 2506
matched pairs in the original propensity score analysis. Table 1
summarizes the prematched and the matched patient popula-
tions. In the full patient population, patients initiating Treatment
2 were on average more likely to be male, have more comorbid-
ities, and use more resources in the 6 months prior to initiation.
After propensity score matching, balance was achieved on all
measured covariates.
A total of 2525 patients (25.1%) had an Hb A1c value obtained
within the 3 months prior or 2 months postinitiation of medica-
tions under study. Rates of missing Hb A1c data were 77.6% for
Treatment 2 and 73.9% for Treatment 1 initiators. Patients
initiating Treatment 2 had significantly higher mean baseline
Table 1 – Demographic and clinical characteristics of patients in the preindex period: Pre and postpropensity score matching.
Prematching Postmatching
Treatment 1
(n ¼ 7,255)
Treatment 2
(n ¼ 2,819)
P Treatment 1
(n ¼ 2,506)
Treatment 2
(n ¼ 2,506)
P
Age (y) at index, mean  SD 52.8  9.2 54.4  10.4 o0.01 53.7  9.4 53.8  10.0 0.72
Gender, n (%) Female 3,933 (54.2) 1,189 (42.2) o0.01 1,050 (41.9) 1,096 (43.7) 0.19
Insurance provider, n (%) o0.01 0.98
Exclusive provider organization 1,168 (16.1) 440 (15.6) 408 (16.3) 405 (16.2)
Health maintenance
organization
760 (10.5) 433 (15.4) 366 (14.6) 357 (14.2)
Independent 184 (2.5) 137 (4.9) 86 (3.4) 94 (3.8)
Point of service 4,520 (62.3) 1,555 (55.2) 1,419 (56.6) 1,424 (56.8)
Preferred provider organization 621 (8.6) 252 (8.9) 225 (9.0) 225 (9.0)
Region, n (%) o0.01 0.93
Midwest 1,802 (24.8) 933 (33.1) 804 (32.1) 801 (32.0)
Northeast 476 (6.6) 215 (7.6) 181 (7.2) 190 (7.6)
South 4,029 (55.5) 1,316 (46.7) 1,218 (48.6) 1,203 (48.0)
West 947 (13.1) 355 (12.6) 303 (12.1) 312 (12.5)
Preperiod resource use, n (%)
Endocrinologist visit 2,040 (28.1) 276 (9.8) o0.01 283 (11.3) 272 (10.9) 0.62
Hospitalizations 436 (6.0) 520 (18.4) o0.01 290 (11.6) 298 (11.9) 0.73
Emergency room visits 450 (6.2) 178 (6.3) 0.05 146 (5.8) 147 (5.9) 0.95
Preindex total health care costs,
mean  SD
9,350  17,740 17,511  39,485.6 o0.01 11,526  25,335.3 11,546  23,421.6 0.97
Diabetes complications
Diabetic retinopathy, eye
disease(glaucoma,
diabetic retinopathy, retinal
bleeding,
cataracts, age-related
macular degeneration)
1,080 (14.9) 467 (16.6) 0.04 404 (16.1) 408 (16.3) 0.88
Renal failure/nephropathy 428 (5.9) 279 (9.9) o0.01 182 (7.3) 191 (7.6) 0.63
Neuropathy 555 (7.6) 205 (7.3) 0.52 161 (6.4) 167 (6.7) 0.73
Amputation and/or foot
ulceration/gangrene
77 (1.1) 61 (2.2) o0.01 37 (1.5) 37 (1.5) 1.00
Macrovascular complications, n (%)
Myocardial infarction 31 (0.4) 49 (1.7) o0.01 20 (0.8) 25 (1.0) 0.45
Ischemic heart disease 815 (11.2) 434 (15.4) o0.01 322 (12.8) 322 (12.8) 1.00
Congestive heart failure 133 (1.8) 170 (6.0) o0.01 83 (3.3) 84 (3.4) 0.94
Peripheral vascular disease 254 (3.5) 146 (5.2) o0.01 109 (4.3) 103 (4.1) 0.67
Stroke 85 (1.2) 66 (2.3) o0.01 46 (1.8) 40 (1.6) 0.51
Other common comorbidities in
diabetes, n (%)
Depression 458 (6.3) 148 (5.3) 0.04 126 (5.0) 128 (5.1) 0.90
Any mental health (excluding
depression)
680 (9.4) 302 (10.7) 0.04 233 (9.3) 230 (9.2) 0.88
Obesity 1,101 (15.2) 265 (9.4) o0.01 258 (10.3) 239 (9.5) 0.37
Hypertensive disease 4,904 (67.6) 1881 (66.7) 0.40 1,623 (64.8) 1,650 (65.8) 0.42
Dyslipidemia 5,368 (74.0) 1887 (66.9) o0.01 1,709 (68.2) 1,716 (68.5) 0.83
Hypoglycemia 130 (1.8) 56 (2.0) 0.52 38 (1.5) 41 (1.6) 0.73
Preperiod Charlson score 1.4 (0.7) 1.6 (1.0) o0.01 1.4 (0.8) 1.4 (0.8) 0.76
Baseline Hb A1c 7.6 (1.6) 9.6 (2.3) o0.01
HbA1c, hemoglobin A1c.
P values correspond to either an independent groups w2 test or an independent groups t test.
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9.5%  2.2% vs. 7.6%  1.5%; Po 0.01). Baseline Hb A1c values in
this sample were found to have only a small association with
outcome (Pearson’s r ¼ 0.07, Spearman’s r ¼ 0.17, Po 0.05 for
both statistics). Some differences were noted in baseline patient
characteristics between patients with and without a baseline
Hb A1c (Table 2). Patients missing Hb A1c values were slightly morelikely to have had a hospitalization in the prior 6 months, while
patients with Hb A1c values were more likely treated by endocri-
nologists. Although it is expected in clinical practice that Hb A1c
values will be obtained for all diabetes patients, these are not
necessarily collected and recorded in the administrative claims
databases. It is unclear what systematic factors drove the entry
of HbA1c values or lack thereof into the claims database
Table 2 – Demographic and clinical characteristics of patients in the preindex period: With and without an Hb A1c
measurement.
Prematching
Missing Hb A1c
(n ¼ 7549)
With Hb A1c data
(n ¼ 2525)
P
Drug (% Treatment 1) 71.0 75.0 o0.01
Age (y) at index, mean  SD 53.6  9.9 52.3  8.8 o0.01
Gender, % Female 50.8 51.1 0.81
Preperiod resource use (%)
Endocrinologist visit 21.7 26.9 o0.01
Hospitalizations 10.3 7.1 o0.01
Emergency room visits 6.2 6.5 0.53
Preindex total health care costs, mean  SD 11,914  26,447 10,796  24,623 0.05
Diabetes complications
Diabetic retinopathy, eye disease (glaucoma, diabetic retinopathy, retinal
bleeding, cataracts, age-related macular degeneration)
15.3 15.6 0.64
Renal failure/nephropathy 7.1 6.9 0.71
Neuropathy 7.6 7.4 0.76
Amputation and/or foot ulceration/gangrene 1.5 1.1 0.13
Macrovascular complications (%)
Myocardial infarction 0.9 0.5 0.04
Ischemic heart disease 12.5 12.0 0.53
Congestive heart failure 3.2 2.4 0.03
Peripheral vascular disease 4.2 3.5 0.12
Stroke 1.6 1.2 0.14
Other common comorbidities in diabetes (%)
Depression 6.0 6.1 0.84
Any mental health (excluding depression) 9.9 9.4 0.53
Obesity 13.6 13.4 0.77
Hypertensive disease 66.2 70.7 o0.01
Dyslipidemia 70.1 77.7 o0.01
Hypoglycemia 1.8 2.1 0.21
Comorbidities scores, mean  SD
Preperiod Charlson score 1.43  0.83 1.39  0.74 0.03
HbA1c, hemoglobin A1c.
P values correspond to either an independent groups w2 test or an independent groups t test.
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treatment selection or outcome.
The original analysis, based on the propensity score matched
sample, found significantly lower total health care costs for
patients initiating Treatment 1 (mean $19,978  $588) as com-
pared with Treatment 2 (mean $22,575  $797) in the 12-month
follow-up period (mean cost difference of $2597 with two-sided
95% confidence interval 690–4542).
Prior to utilizing the internal information, a Rule Out [10]
assessment was performed (Figure 1). Results demonstrated that
a single confounder would need to have a strong relationship
with either outcome or treatment selection to eliminate the
observed treatment difference. The line in Figure 1 represents
combinations of confounding (unmeasured confounder to treat-
ment and unmeasured confounder to outcome) that would
generate an observed treatment difference of $2597 despite a
true treatment effect of zero. For instance, a combination of
association with outcome of approximately $26,000 (patients
with confounder cost an average of $26,000 more per year than
do patients without the confounder) and association with treat-
ment selection of 10% (confounder is present in 10% more
patients in Treatment 2 as compared with Treatment 1) would
be able to explain the observed treatment difference of $2597.
However, any confounding of less strength, represented by areas
below and to the left of the line, would not have been sufficienton its own to produce the observed treatment difference. An
alternative would be to alter the line of Figure 1 to represent the
level of confounding necessary to produce a value equal to the
lower 95% confidence interval limit (instead of the estimate
itself). The graph would then reflect the confounding levels
sufficient to eliminate the statistical significance of the findings.
The validity of the surrogacy assumption for PSC was ques-
tionable. The likelihood ratio test suggested that PSEP was not
independent of outcome given PSGS and treatment (Po 0.01).
This was likely because the direction of the confounding from the
unmeasured confounder (Hb A1c was positively associated with
treatment and negatively associated with outcome; r ¼ 0.17)
was in the opposite direction as the confounding from the
existing covariates (covariates were positively associated with
treatment and with outcome: Spearman, range 0.06 to 0.49).
While the results were reasonably consistent with the other
methods (differences of $1638 and $2343 with matching and
stratification), PSC can give aberrant results in this situation [20].
Figure 2 summarizes the results from the unmeasured con-
founding sensitivity analyses utilizing the subset Hb A1c informa-
tion based on the Bayesian models and multiple imputation as
compared with the original propensity score matching approach.
Results from these approaches were consistent with the original
analysis. For instance, the multiple imputation approach pro-
vided an estimated treatment difference of $2534 (two-sided 95%
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Fig. 1 – Rule Out analysis. Area above and right of the plotted
line represents values of the levels of confounding that would
produce an observed $2597 (or greater) treatment difference
even with a true treatment effect of zero. Area below and left
of the plotted line represents levels of confounding that
would not be sufficient on its own to produce the observed
difference. Pc1, prevalence of the unmeasured confounder in
treatment cohort 1; Pc2, prevalence of the unmeasured
confounder in treatment cohort 2.
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data would not substantially change the observed results. The
number of patients matched by the propensity score algorithm
varied slightly with each imputation, but averaged 4982, only a
small reduction from the 5012 in the original analysis. Similar to
the multiple imputation results, the posterior distribution from
Bayesian modeling on the propensity matched population
yielded a treatment difference estimate of $2149 with credible
region of (348, 4001).-500
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Fig. 2 – Unmeasured confounding sensitivity assessment: Baye
two-sided 95% confidence intervals/credible regions (bars) for th
costs are presented for the original analysis and for analyses in
data: Bayesian regression modeling and multiple imputation. P
so results are questionable; results included here for comparison
approximately 40% less due to the lack of propensity matches bConclusions
The lack of unmeasured confounders is a critical assumption
underpinning the validity of comparative observational research.
However, the quantitative assessment of the potential impact of
unmeasured confounding is rarely reported. In this research, we
have summarized and expanded on some of the existing meth-
ods for addressing unmeasured confounding. This work focused
on situations in which internal data were available; that is, the
confounder was not completely ‘‘unmeasured,’’ but some limited
data were available. The methods were demonstrated by using
a health care claims database analysis of type 2 diabetes
medications.
The results of this analysis suggested that the missing Hb A1c
data had only a modest impact on the original analysis. This
result is not surprising given the lack of strong correlation
between baseline Hb A1c and cost in this population. Results
with a stronger confounder would be expected to have a much
more tangible impact on the final analysis—as indicated by the
Rule Out procedure. Of course, this work is based on a single
example and should not be taken to imply a lack of importance
of assessing the potential impact of confounders in general. Note
also that only the potential impact of the missing glycemic
control information was assessed in a quantitative fashion. Other
known potential confounders, such as BMI and duration of
diabetes, were also unavailable in this claims database. Literature
suggests that patients with higher BMIs are more costly [27,28],
and this would likely make the treatment difference larger as
patients with a higher BMI/weight are more likely to be pre-
scribed Treatment 1 [29]. Yu et al. [28] estimated a $213/y
reduction in health care costs following a 1% reduction in weight.
Regarding duration of diabetes, Trogdon and Hylands [30] utilized
Medical Expenditure Panel Survey data and estimated that each
additional year with diabetes increases health care costs by
approximately $158. Thus, this confounder could be expected to
shrink the observed effect—under the assumption that age is
correlated with the duration of diabetes and patients prescribedMultiple Imputation Propensity Calibration*
Stratification
Matching
sian and multiple imputation results. Point estimates and
e estimated treatment difference in total 1-year health care
corporating confounding due to missing glycemic control
ropensity calibration surrogacy assumption was not met, and
purposes. Note that the sample size for this analysis was
etween the cohorts.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 2 5 9 – 2 6 6 265Treatment 2 tended to be older (though the use of age may
partially account for this unmeasured confounder). In addition,
information from a previous head-to-head randomized trial of
these treatments suggested similar changes in Hb A1c though
some differences in side effect profiles [31]. As discussed in
Appendix 1 in Supplemental Materials found at doi: 10.1016/
j.jval.2012.10.012, the Bayesian modeling proposed here is flexible
and can incorporate external information through the prior
distributions, but such analyses are beyond the scope of this
research.
Settings in which internal data are available include situa-
tions like that in our example where there was substantial
missing data for a few variables (where they are for practical
purposes considered ‘‘unmeasured’’) or where subsampling from
the population was done to collect additional data—such as chart
review on a subset of the sample in health care claims database
research. In settings in which internal data will not be available
without significant additional expense, it is critical to understand
when (and how much) the additional data would add sufficient
value to justify the cost. It may well be that a more feasible
approach is to use external data, that is, data from other research
that contains information on both the unmeasured confounder
and the outcome variable, particularly data from randomized
pragmatic studies. Of course, external data methods make the
assumption of transportability across study populations and
typically do not take into account correlations among the multi-
ple covariates already in the study. Thus, there is a trade-off and
additional work is needed to guide researchers in this area.
Simple approaches such as the Rule Out method can be useful
as an initial assessment of unmeasured confounding. They are
intuitive and can be used in all situations as there is no required
additional information on the unmeasured confounder. When
additional data exist regarding the unmeasured confounders,
however, other methods could be more informative. In addition,
the Rule Out approach can assess the impact of only a single
unmeasured confounding variable.
For this current analysis, PSC did not provide a valid assess-
ment of unmeasured confounding as the assumption of surro-
gacy was questionable. From our perspective, this assumption
can limit the applicability of this method. For a given setting,
there may be no a priori reason why the unmeasured confounder
would have to have the same directional effect on the outcome as
the measured confounders.
Multiple imputation and Bayesian approaches appear to be
useful tools when internal information exists for the unmeasured
confounding. Multiple imputation is a well-accepted approach for
cases in which the amount of missing data is reasonably limited,
but its validity in these settings, where the amount of missing
data is the majority, is less well studied. Like PSC, this approach
utilizes the existing relationships with the other covariates in the
analysis. As this work is based on an actual data set and not a
simulation, the true treatment effect in our example is unknown.
Without knowing the truth we are really unable to establish that
the methods performed well or would have been able to identify
the negative impact of an unmeasured confounder under a
stronger confounding situation. Simulation studies are clearly
needed to understand the operating characteristics of these
approaches under a variety of scenarios and answer questions
such as the requisite subsample size.
Bayesian methods provide a flexible approach to studying
unmeasured confounding. They can utilize all sources of infor-
mation, both internal and external, while simultaneously model-
ing attendant uncertainty. Internal data can reduce the need to
use informative prior distributions. Prior distributions con-
structed by using internal data, however, could be enhanced
with external data and expert opinion. All this is completely
transparent, so that the consumer of a Bayesian sensitivityanalysis is easily made aware of the model’s overall structure
and operating assumptions.
This work suffers from several limitations, starting with the
usual difficulties plaguing the use of health care claims data-
bases. Such data are not collected for research purposes, are
subject to coding biases, and lack validated diagnoses and
information about clinical severity, genetic information, and
socioeconomic influences. This study examined unmeasured
confounding only for glycemic control (measured by Hb A1c) as
Hb A1c values were reported for a subgroup of patients. Other
potential unmeasured confounders common when using claims
database such as weight, BMI, and duration of diabetes were not
controlled for or studied in this research as no data were
available in the database. Treatment cohorts were based only
on the initiation of the new medication, and no attempt was
made to control for concomitant antidiabetic medication use
after initiation or medication switching. Causal inference ana-
lyses incorporating postbaseline medication changes would
require more complex analyses with additional assumptions,
such as marginal structural modeling [32]. In addition, our work
examined only a single scenario, and we therefore cannot
provide guidance about appropriate methods in other scenarios.
Practical issues, such as the impact of representativeness and the
size of the internal data set, have also not been addressed here.
The subsample of patients with Hb A1c data was not randomly
selected, and the impact of this is unknown. While we have
provided an example of several methods for a particular setting, a
thorough evaluation of the operating characteristics of each
method remains. Other potential approaches, such as using the
missingness itself as a proxy for confounding, should also be
examined. Extensive simulation studies will be needed to study
such issues. We hope that our example will motivate future
research.
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